Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia

Case report: The efficiency and safety of lomitapide in a homozygous familial hypercholesterolemic child

(2019) Ana Paula M. Chacra et al.   Journal of Clinical Lipidology

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data

(2018) Steve E. Humphries et al.   Journal of Clinical Lipidology

LONG-TERM SAFETY AND EFFICACY OF LOMITAPIDE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: THREE-YEAR DATA FROM THE LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER)

(2018) James Underberg et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia

(2018) Dirk J. Blom et al.   Orphanet Journal of Rare Diseases

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review

(2018) Ilse K. Luirink et al.   Journal of Clinical Lipidology

The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis

(2017) Robert Leipold et al.   European Journal of Preventive Cardiology

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

(2017) Frederick J Raal et al.   Lancet Diabetes & Endocrinology

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

(2016) Patrick M. Moriarty et al.   EUROPEAN HEART JOURNAL

Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort

(2016) M. Averna et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

(2016) Raul D Santos et al.   Lancet Diabetes & Endocrinology

Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide

(2015) Jeanine Roeters van Lennep et al.   Journal of Clinical Lipidology

Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: Insights from a patient survey

(2014) Eric Bruckert et al.   ATHEROSCLEROSIS SUPPLEMENTS

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

(2014) M. Cuchel et al.   EUROPEAN HEART JOURNAL

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

(2012) Marina Cuchel et al.   LANCET

Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe

(2010) Gilbert R Thompson et al.   CURRENT OPINION IN LIPIDOLOGY

Efficacy criteria and cholesterol targets for LDL apheresis

(2009) Gilbert R. Thompson et al.   ATHEROSCLEROSIS

Long-Term Safety and Efficacy of Low-Density Lipoprotein Apheresis in Childhood for Homozygous Familial Hypercholesterolemia

(2008) Lisa C. Hudgins et al.   AMERICAN JOURNAL OF CARDIOLOGY

PCSK9: a convertase that coordinates LDL catabolism

(2008) Jay D. Horton et al.   JOURNAL OF LIPID RESEARCH